Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business

Myriad Genetics (MYGN) shares rose 36.94% to $5.77 on news of selling its Prenatal Health testing business to Labcorp (LH) for $210M in cash. The deal, expected to close in early 2027, is projected to boost MYGN's revenue growth and profitability, according to the company. Labcorp anticipates $160M in revenue from the acquisition in its first year.

Original reporting
Published Oct 20, 2026, 5:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 6:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business — source image
Decision brief

The 30-second read

$MYGNBullishHigh
01

Why it matters

The transaction provides Myriad with cash to fund its core oncology portfolio and gives Labcorp a broader women's health offering.

02

Market read

The deal is material for both companies, moves Myriad shares sharply higher, and adds revenue to Labcorp, making it a high‑impact M&A news item.

03

What to watch

Regulatory clearance risk and integration execution could delay expected revenue and earnings accretion for Labcorp.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Myriad Genetics is a molecular diagnostics company focusing on cancer genetics; Labcorp is a leading national laboratory services provider.

Company-level read

Ticker impact

$MYGNBullishHigh confidence
Context

Myriad Genetics announced a definitive agreement to sell its Prenatal Health testing business to Labcorp for $210 million in cash, driving a 36.9% intraday price surge.

Expected impact

likely upward pressure as the market prices in the cash proceeds and strategic focus on cancer diagnostics

Evidence & confidence

Deal size is material, cash component is sizable for a mid‑cap, and the stock already rallied sharply on the news.

$LHBullishMedium confidence
Context

Labcorp entered into a definitive agreement to acquire Myriad's Prenatal Health testing business for $210 million, adding an estimated $160 million of revenue in year one.

Expected impact

moderate upside as investors value the revenue boost and strategic fit

Evidence & confidence

Revenue add‑on is modest relative to Labcorp's scale, but the deal aligns with its growth strategy.

Market effects

Consolidates the reproductive genetics niche under Labcorp, potentially prompting further M&A activity in molecular diagnostics.

U.S. healthcare and diagnostics sector sees a positive reallocation of capital.

Highlights continued strategic realignment in the global molecular diagnostics market.

Counterpoint

Some investors may view the divestiture as a signal that Myriad's prenatal segment underperformed, questioning long‑term growth prospects.

Key entities

  • Myriad Genetics

    Seller of the Prenatal Health testing business.

  • Labcorp

    Buyer of the Prenatal Health testing business.

Related articles

$LHHighAI 9/10

Labcorp completes $375M Millennium Health takeover

Labcorp completed its $375M acquisition of Millennium Health, including $245M upfront and up to $130M in milestone payments. The deal aims to enhance Labcorp's toxicology services and expand its geographic reach. Millennium specializes in drug testing, complementing Labcorp's existing offerings. Labcorp CEO Adam Schechter highlighted the strategic fit and growth potential during an earnings call.

$LHMed

Labcorp Finalizes Acquisition of Millennium Health to Expand Toxicology Testing

Labcorp has completed its acquisition of Millennium Health, a specialty lab focused on drug testing and surveillance. The deal aims to expand Labcorp's toxicology testing capabilities nationwide, providing insights for treating chronic pain, substance use disorders, and mental health conditions. Labcorp expects to integrate Millennium's expertise with its own network and digital solutions to improve patient care.